Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 15 of 15

Download this page as JSON

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Plasma Exchange vs No Plasma Exchange: Number of Participants With Sustained Remission	200 of 352	197 of 352	704	NCT00987389	Trial comparisons
Plasma Exchange vs No Plasma Exchange: Composite of i) All-cause Mortality or ii) End-stage Renal Disease	100 of 352	109 of 352	704	NCT00987389	Trial comparisons
Plasma Exchange vs No Plasma Exchange: deaths from any cause	46 of 352	53 of 352	704	NCT00987389	Trial comparisons
Plasma Exchange vs No Plasma Exchange: serious adverse events	225 of 352	224 of 352	704	NCT00987389	Trial comparisons
Prednisone Group vs Avacopan Group: Number of Subjects With Clinically Significant ECG Changes From Baseline	8 of 164	12 of 166	330	NCT02994927	Trial comparisons
Prednisone Group vs Avacopan Group: deaths from any cause	4 of 164	2 of 166	330	NCT02994927	Trial comparisons
Prednisone Group vs Avacopan Group: serious adverse events	74 of 164	70 of 166	330	NCT02994927	Trial comparisons
Prednisone Group vs Avacopan Group: Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study	33 of 157	16 of 158	315	NCT02994927	Trial comparisons
Belimumab 10 mg/kg vs Placebo: deaths from any cause	1 of 53	0 of 52	105	NCT01663623	Trial comparisons
Belimumab 10 mg/kg vs Placebo: Number of Participants With Major Relapse During the Double-blind Phase of the Study	1 of 53	0 of 52	105	NCT01663623	Trial comparisons
Belimumab 10 mg/kg vs Placebo: serious adverse events	18 of 53	16 of 52	105	NCT01663623	Trial comparisons
Intravenous Dose of Obinutuzumab vs Intravenous Dose of Rituximab: deaths from any cause	0 of 2	0 of 4	6	NCT05376319	Trial comparisons
Intravenous Dose of Obinutuzumab vs Intravenous Dose of Rituximab: serious adverse events	1 of 2	0 of 4	6	NCT05376319	Trial comparisons
Intravenous Dose of Obinutuzumab vs Intravenous Dose of Rituximab: Number of Patients to Achieve Sustained Complete Remission 6 Months	1 of 1	0 of 1	2	NCT05376319	Trial comparisons
Intravenous Dose of Obinutuzumab vs Intravenous Dose of Rituximab: Number of Patients to Achieve Both Complete Remission and Seronegativity for ANCA.	0 of 1	0 of 1	2	NCT05376319	Trial comparisons

diseases-2026-09-18-0.1.0

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015492/comparisons

API reference For AI assistants